Company profile: Orpyx
1.1 - Company Overview
Company description
- Provider of sensor-based technologies and self-monitoring devices for medical and athletic applications, including the Orpyx SI Sensory Insole System to monitor plantar pressure, adherence, step count, and temperature for peripheral neuropathy patients to reduce diabetic foot ulcer risk. Offers remote patient monitoring with data science-based triage by credentialed providers and nurses and a Diabetes Healthspan Extension for personalized remote care.
Products and services
- Diabetes Healthspan Extension: Remote-care service that extends healthspan for individuals living with diabetes through personalized care, focusing on preventing complications and improving quality of life
- Orpyx SI Sensory Insole System: Sensor-integrated, wearable system that monitors plantar pressure, adherence, step count, and temperature for peripheral neuropathy patients to reduce diabetic foot ulcer risk
- Remote Patient Monitoring Services: Data-science-driven service that tracks patient data and delivers personalized support by credentialed providers and nurses, enabling triaged clinical escalation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Orpyx
Poxel
HQ: France
Website
- Description: Provider of biopharmaceutical products for metabolic diseases, focusing on type 2 diabetes and NASH. Portfolio includes TWYMEEG (Imeglimin), approved in Japan for type 2 diabetes, targeting mitochondrial dysfunction; PXL065, a deuterium-stabilized R-pioglitazone for NASH with Phase 2 primary endpoint met; and PXL770, a direct AMPK activator for rare diseases including NASH and ALD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Poxel company profile →
GI Dynamics
HQ: United States
Website
- Description: Provider of endoscopically delivered medical devices for managing type 2 diabetes, obesity, and related metabolic diseases, including RESET, which creates a barrier in the small intestine to improve insulin resistance and glycemic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GI Dynamics company profile →
Sigrid THx
HQ: Sweden
Website
- Description: Provider of ingested medical devices and platform technologies to lower blood sugar in prediabetics and newly diagnosed type 2 diabetics. Offerings include SiPore21 and the SiPore platform using engineered silica particles acting in the gut without absorption. Conducts clinical trials, including SiPore15 and SiPore21, with potential future indications in obesity, NASH, and infantile colic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigrid THx company profile →
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
Sensulin
HQ: United States
Website
- Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensulin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Orpyx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Orpyx
2.2 - Growth funds investing in similar companies to Orpyx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Orpyx
4.2 - Public trading comparable groups for Orpyx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →